AI Article Synopsis
- - The management of hepatic adenoma in transgender individuals on hormone therapy is not clearly defined, particularly in relation to sex assigned at birth versus the therapy received.
- - A case study is presented involving a transgender man who experienced hepatic adenomatosis with a molecular profile different from typical cases seen in cisgender males on testosterone.
- - Discontinuing testosterone led to the self-resolution of the adenoma, suggesting the need for personalized treatment strategies in transgender patients, challenging the current norms based on biological sex.
Article Abstract
The management of hepatic adenoma in transgender individuals undergoing gender-affirming hormone therapy remains unclear, especially whether treatment should be based on sex assigned at birth or therapy patient received. We presented a transgender man, female at birth, with hepatic adenomatosis with molecular profile differed from typical adenomas in cisgender males on testosterone. Discontinuing testosterone led to autoinfarction of the adenoma, allowing the avoidance of invasive treatments and resumption of gender-affirming hormone therapy. This case underscores the necessity for personalized care in the growing transgender population and challenges current consensus of treatment based on sex assigned at birth, emphasizing a tailored approach.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390042 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000001483 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!